Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has struck a vital breakthrough with its drug for Cystic Fibrosis, as we have recently reported.Now it’s time to find out what’s in store for the company in the future.
Meg Tirrell, CNBC’s Business news started talking about the Cystic Fibrosis Drugs and how they work. Tirrell started by saying that Cystic Fibrosis drugs have met and even exceeded the expectations. She also said that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has reported positive trend. This drug is a combo of medicines that improves lung function in patients with Cystic Fibrosis.
Cystic Fibrosis is caused by mutations in a gene known as CFTR. When the gene is defective, the protein it creates can’t help chloride escape the cell and that hampers the movement of fluid across the cell wall and leads to production of thick mucus across the airways and other areas. The first medicine to address this is Kaledyco, which restores the protein’s ability to allow chloride to pass through the cell membrane. Only 200 CF patients can get benefited from this drug. Many more have a bigger problem. The protein can’t get to the membrane at all, so Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is testing a new drug, Lumacaftor. Lumacaftor aims to get the protein to the cell wall, whereas Kaledyco opens the passage for chloride. A combination of both drugs could help around 28000 people, which is 14 times as many as Kaledyco alone could do.
The analysis says that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) drugs could bring in $5 million in peak sales and the data also gave a sentimental boost across the biotech sector.
Matt Radon, Executive director and senior analyst at UBS, was on CNBC on Tuesday and he was asked if there is more upside to Vertex Pharmaceuticals Incorporated (NASDAQ